Technology Being Challenged by Upsurge in Decentralized Clinical Trials
MANASSAS, Va., April 5, 2022 /PRNewswire-PRWeb/ -- Clinical trials in certain common serious diseases are on track for their first year-over-year increase since the outbreak of the COVID-19 pandemic. Among areas slated for significantly increased testing are diabetes, hypertension, and respiratory tract infection. Along with these activities will come a marked increase in decentralized clinical trial design, expected to increase 28% this year over 2021.(1) "By joining forces to enable the increased growth of decentralized studies," says Dr. Harsha Rajasimha, founder and CEO of Jeeva Informatics, "technology companies are transforming the face of medical research. The remotely managed, decentralized clinical trial is the wave of the future."
- There has been, he notes, a growing awareness of the need for decentralized clinical trials for some time.
- A few years back, for example, the National Academies of Sciences convened a forum on transforming clinical trials through technology.
- New technology such as wearable devices, remote monitoring, and virtual clinical visits could make Clinical Trials more patient-focused.
- The accelerated process used for COVID-19 trials has conclusively demonstrated both the need for and the efficacy of decentralized clinical trials.